Replies to post #4525 on Dendreon Corp fka DNDNQ

[walldiver]

re CEGE: I can't see GVAX surviving the first interim look of VITAL-1, but stranger things have happened. As it appears to be a superiority trial (with no crossover allowed in either arm), the median survival target to beat is Taxotere's 23.0 months (no bone pain subgroup of TAX-327 Phase III). Even Provenge would have a tough time in trying to beat 23 months MS in a stat sig manner. Anyway, FWIW, I think VITAL-1 will be stopped for futility at the first interim look. For the sake of future HRPC patients, I hope I'm wrong.